Early results from a clinical trial suggest that adding pazopanib (Votrient) to chemotherapy and radiation before surgery may be a promising treatment option for children and adults with advanced soft tissue sarcoma.
A CAR T-cell therapy called brexucabtagene autoleucel (Tecartus) has been approved by the Food and Drug Administration (FDA) for some patients with mantle cell lymphoma. This is the third CAR T-cell therapy approved for patients with cancer.
Regular use of low-dose aspirin may increase an older person’s risk of being diagnosed with advanced cancer and of dying from cancer, results from the ASPREE clinical trial suggest. Learn more about what this 19,000-participant study found.
For some women with HER2-positive uterine serous carcinoma, a rare type of endometrial cancer, treating them with trastuzumab (Herceptin) and chemotherapy may help them live longer, according to updated results from a small clinical trial.
Clinical Trials Information for Patients and Caregivers
Clinical trials to test new cancer treatments involve a series of steps, called phases. If a new treatment is successful in one phase, it will proceed to further testing in the next phase.
In some phase 2 and all phase 3 clinical trials, patients are assigned to groups that receive different treatments. The process of assigning patients to these groups by chance is called randomization.
This phase 2 trial will study how well an ALK inhibitor works in treating people with metastatic ALK-positive non-squamous non-small cell lung cancer that has developed resistance to a first line ALK inhibitor. Patients will be treated with one of nine ALK-inhibiting drugs based on the type of genetic alterations in their tumors. The trial is also evaluating the effectiveness of liquid biopsies to detect ALK alterations in circulating cell-free DNA in blood to corroborate the ALK alterations detected by tumor biopsies.
This phase 1/2 trial will test an experimental drug called M7824 alone or combined with other experimental immunotherapies for people with newly diagnosed squamous cell carcinoma of the head and neck not caused by HPV. Doctors want to see if M7824 alone or combined with other immune targeted drugs will shrink head and neck tumors before surgery or stop the tumors from coming back after all treatment is completed.
This phase 3 trial will test controlled-release bupropion in women experiencing cancer-related fatigue after completing treatment for stage 1, 2, or 3 breast cancer. Women with breast cancer who have completed surgery, radiation therapy, or chemotherapy will be assigned by chance to receive either bupropion or a placebo. Doctors want to see if taking bupropion will reduce fatigue and depression and improve quality of life.
